Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

109 results about "Human neutrophil" patented technology

Neutrophils are the most abundant white blood cells in humans (approximately 10 11 are produced daily); they account for approximately 50–70% of all white blood cells (leukocytes). The stated normal range for human blood counts varies between laboratories, but a neutrophil count of 2.5–7.5 x 10 9 /L is a standard normal range.

Kunitz domain peptides

The invention relates to a Kunitz domain peptide, designated DPI-14 herein, for inhibiting human neutrophil elastase. The invention also relates to a method of using a DPI-14 for treating cystic fibrosis or cystic fibrosis-related disease or disorder.
Owner:TAKEDA PHARMA CO LTD

Tetrahydropyrrolopyrimidinediones and their use in therapy

Compounds of formula (I) and multimers thereof are inhibitors of human neutrophil elastase activity, and of utility in the treatment of, e.g., COPD:wherein A is aryl or heteroaryl; D is oxygen or sulphur; R1, R2 and R3 are independently each hydrogen, halogen, nitro, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, hydroxy or C1-C6-alkoxy or C2-C6-alkenyloxy, wherein C1-C6-alkyl and C1-C6-alkoxy can be further substituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy and C1-C4-alkoxy;R and R4 each independently represent a radical of formula—[X]m-[Alk1]p-[Q]n-[Alk2]q-[X1]k-Z wherein k, m, n, p and q are independently 0 or 1; Alk1 and Alk2 each independently represent an optionally substituted C1-C6 alkylene, or C2-C6 alkenylene radical which may optionally contain an ether (O—), thioether (—S—) or amino (—NRA—) link wherein RA is hydrogen or C1-C3 alkyl; Q represents (i) O—, —S—, —S(═O)—, —S(═O)2—, —S+(RA)—, —N(RA)—, —N+(RA)(RB)—, —C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)NRA—, —NRAC(═O)—, —S(O2)NRA—, —NRAS(O2)—, —NRAC(═O)NRB—, —NRAC(═NRA)NRB—, —C(═NRD)NRE, —NREC(═NRD), wherein RA, RB, RD and RE are independently hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl, or RA and RB, or RD and RE taken together with the nitrogen to which they are attached form a monocyclic heterocyclic ring of 5 to 7 ring atoms which my contain a further heteroatom selected from N, O and S, or (ii) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 3-6 ring members; X represents —(C═O)—, —S(O2)—, —C(═O)O—, —(C═O)NRA—, or —S(O2)NRA—, wherein RA is hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl; X1 represents —O—, —S—, or —NH; and Z is hydrogen or an optionally substituted mono- or bicyclic carbocyclic or heterocyclic radical having 3-6 ring members.
Owner:CHIESI FARM SPA

Novel compounds

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated.
Owner:CHIESI FARM SPA

Detection kit for neutrophil gelatinase-associated lipocalin

The invention discloses a detection kit for neutrophil gelatinase-associated lipocalin. The detection kit comprises a detection liquid and a standard substance, wherein the detection liquid comprises latex particles coupled with an anti-human neutrophil gelatinase-associated lipocalin antibody; the standard substance is naturally configured recombinant neutrophil gelatinase-associated lipocalin. The detection kit measures the content of the neutrophil gelatinase-associated lipocalin through a latex particle intensified immunity turbidity, and compared with the traditional NGAL detection kit, the detection kit has the advantages of high detection sensitivity, high simpleness in operation, good repeatability and short time consumption, does not need sample pretreatment, and can be used for a fully automatic biochemical analyzer.
Owner:FAPON BIOTECH INC

Human neutrophil collagenase splice variant

InactiveUSH1973H1Reduce and prevent effect of MMP-8altInhibit expressionSugar derivativesHydrolasesApoptosisArthritis
The subject invention is related to human MMP-8alt genes and gene products and their differential expression when comparing a patient with a disease state to a control. A further aspect of the invention concerns compounds which antagonize the biological activity of MMP-8alt protein and methods for identifying these compounds. Another aspect of the present invention concerns pharmaceutical compositions comprising such compounds for the treatment of arthritis, cancer, and disease caused by cellular apoptosis including but not limited to Parkinson's disease, Alzheimer's disease and Huntington's chorea.
Owner:NOVARTIS AG

A test kit for detecting periodontal disease

Test kit for diagnosing periodontal disease in a patient by analysing a sample from the oral cavity of the patient. The test kit comprises at least a first detection assay for detection of a first substance originating from bacteria and at least a second detection assay for detection of a second substance originating from the immune or inflammatory system of the patient. Most preferably, said first substance is a bacterial virulence product such as e.g. arg-gingipain from Prophyromonas gingivalis, and said second substance is human neutrophil elastase.
Owner:TENDERA

Mouse anti-human neutrophil gelatinase-associated lipocalin (NGAL) monoclonal antibodies and hybridoma cell strains and application thereof

The invention discloses a hybridoma cell strain 3B1 and a hybridoma cell strain 4C2 and a mouse anti-human NGAL monoclonal antibody 3B1 and a mouse anti-human NGAL monoclonal antibody4C2 produced respectively. The two kinds of monoclonal antibodies belong to a same immunoglobulin G (IgG) 2a subclass, but identify various epitopes and can perform specific binding to NGAL recombinant protein with amino acid sequences represented by SEQ ID NO.1. The two monoclonal antibodies can be applied to detect the concentration of the NGAL in human body fluids and have significant application prospect.
Owner:GETEIN BIOTECH

Neutrophil gelatinase-associated lipocalin determination kit

The invention discloses a neutrophil gelatinase-associated lipocalin determination kit. The kit comprises a reagent R1 and a reagent R2 which are liquid components and are mutually independent, the reagent R1 comprises a buffer solution, inorganic salt ions, an accelerator, a chelating agent, a stabilizer, an antiseptic and an anti-humanr heumatoid factor antibody, and the reagent R2 comprises the buffer solution, the stabilizer, a suspending aid, a surfactant, the antiseptic and a latex coated anti-human neutrophil gelatinase-associated lipocalin. The preparation method comprises the following steps: preparing the reagents according to the component content; mixing a sample to be determined with the reagent R1 and the reagent R2 to fully react the sample to be determined with the reagent R1 and the reagent R2; determining the absorbance difference by using a fully-automatic biochemical analyzer after the reaction; and calculating the concentration of neutrophil gelatinase-associated lipocalin in the sample according to the absorbance change value. The kit has high accuracy.
Owner:ANHUI IPROCOM BIOTECH CO LTD

Mammalian-derived peptides for the treatment of microbial infection

The present invention provides compositions useful as antimicrobial agents which include mammalian hemoglobin, the alpha and beta chains of hemoglobin free of heme, fragments of the alpha and beta chains that result from cyanogen bromide cleavage of the alpha and beta chains, and synthetic peptides derived therefrom. The compositions exert antimicrobial activity against both bacteria and fungi that is comparable to known antimicrobial peptides from human neutrophils, cathepsin G and azurocidin. Sensitive organisms include Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa, Gram-positive bacteria such as Staphylococcus aureus and Streptococcus faecalis, and the fungus Candida albicans. Methods for preparing the compositions also are provided.
Owner:THERAGEM

B cell epitope peptide of human neutrophil gelatinase associated lipocalin and application thereof

The invention belongs to the medical field and particularly relates to an acute kidney injury diagnosis technology, a B cell epitope peptide of human NGAL (Neutrophil Gelatinase Associated Lipocalin) and a hybridoma cell prepared by same, and an application of the B cell epitope peptide and a specific antibody thereof and an immune complex of the specific antibody in preparing diagnostic reagent for acute kidney injury. The B cell epitope peptide prepared by the invention immunizes a monoclonal antibody prepared by adopting a rat and has the advantages of high purity (The SDS (Sodium Dodecyl Sulfate)-PAGE (PolyAcrylamide Gel Electrophoresi) detection purity is more than 96 percent), high valence (the ELISA (Enzyme-Linked Immuno Sorbent Assay) valence reaches 1:256000), good specificity, mass preparation and the like; and through the monoclonal antibody and a polyclonal antibody prepared by the B cell epitope peptide, the B cell epitope peptide can be used for detecting the content of the NGAL in the urine of a patient, for example, by adopting a double antibody sandwich ELISA reaction mode, a double antibody sandwich structure formed by an enzyme labeled human anti-NGAL monoclonal antibody, an enzyme labeled plate package anti-NGAL polyclonal antibody and a measured sample NGAL antigen is detected.
Owner:重庆业为基生物科技有限公司

Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
Owner:ASTRAZENECA AB

Novel Superactive IL-33 Fragments, and Uses Thereof

ActiveUS20140099280A1Antibacterial agentsSenses disorderCathepsin KCathepsin G
The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.
Owner:CENT NAT DE LA RECHERCHE SCI

Magnetic nanoparticle immobilized with anthrax lethal factor on surface as well as preparation method and application of magnetic nanoparticle

The invention discloses a magnetic nanoparticle immobilized with an anthrax lethal factor on a surface as well as a preparation method of the magnetic nanoparticle and application of the magnetic nanoparticle in enrichment of human neutrophil peptides. The magnetic nanoparticle immobilized with the anthrax lethal factor on the surface is obtained by connecting the anthrax lethal factor to the surface of the superparamagnetic nanoparticle with amino and / or carboxyl on surface by virtue of amino-carboxyl coupling reaction; the magnetic nanoparticle can quickly and specially enrich the human neutrophil peptides for further detection, so that application of the human neutrophil peptides as tumor prognosis biomarkers is convenient, and therefore, clinical application prospect is very good.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Human alpha-defensins inhibit interleukin-1beta release

Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1β post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human α-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human α-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-1β.
Owner:AUBURN UNIV

Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone

The presence of the ancient anti-inflammatory peptide α-melanocyte stimulating hormone (α-MSH [1-13], SYSMEHFRWGKPV) in barrier organs such as gut and skin suggests a role in the nonspecific (innate) host defense system. α-MSH and other amino acid sequences derived from α-MSH were determined to have antimicrobial influences, including against two major and representative cutaneous and mucosal pathogens: Staphylococcus aureus and Candida albicans. C-MSH peptides had antimicrobial effects against S. aureus and significantly reversed the enhancing effect of urokinase on S. aureus colony formation. α-MSH and other amino acid sequences reduced C. albicans viability and germination. α-MSH peptides also enhanced C. albicans killing by human neutrophils. The antimicrobial agent is selected from the group consisting of one or more peptides including the amino acid sequence KPV, one or more peptides including the amino acid sequence MEHFRWG, or a biologically functional equivalent of any of the foregoing. The most effective of the peptides were those bearing the C-terminal amino acid sequence of α-MSH, i.e., α-MSH (1-13), (6-13), and (11-13). The α-MSH “core” sequence (4-10), important for melanotropic effects, was also effective but significantly less potent. Antimicrobial influences of α-MSH peptides could be mediated by their well-known capacity to increase cellular cAMP; this messenger was significantly augmented in peptide-treated yeast. α-MSH has potent anti-inflammatory effects and is expected to be useful for treatment of inflammation in human and veterinary disorders. Reduced killing of pathogens is a detrimental consequence of therapy with corticosteroids and nonsteroidal anti-inflammatory drugs during infection. Therefore, anti-inflammatory agents based on α-MSH peptides that do not reduce microbial killing, but rather enhance it, would be very useful. The antimicrobial effects of these α-MSH peptides occurred over a broad range of concentrations including the physiological (picomolar) range.
Owner:ZENGEN

Method for determining mucosal neutrophil counts in neutropenia patents

Based on recent investigations showing iatrogenic, profound neutropenia (and the fever spikes that often accompany it, which must be medicated immediately to avoid the risk of life-threatening infection) can most accurately be monitored by obtaining daily mucosal neutrophil counts from the patient's oral mucosa rather than obtaining daily counts of the patient's blood neutrophils as in the past, a mouth wash method has been developed for collecting muscosal neutrophils. The mouth wash samples so collected are delivered directly, or in aqueous dilution to a sample pad supported on a strip which sample pad has deposited thereon reagents enabling a colorimetric, fluorescent or chemiluminescent assay of the quantity of an enzyme characteristic of human neutrophils that is present in the sample. This measured quantity can be correlated to mucosal neutrophil count. The method shows outstanding sensitivity, precision and accuracy relative to microscopic methods of counting mucosal neutrophils.
Owner:WRIGHT DANIEL G +2

Method for treating septicemia with human neutrophil peptide (HNP) blocking agents

InactiveCN102552306AReduce pathogenicityInhibition and Elimination of Pathogenic EffectsAntibacterial agentsOrganic active ingredientsChemical synthesisDisease
The invention discloses a method for treating septicemia with human neutrophil peptide (HNP) blocking agents. The method comprises the following steps of: preparing small interfering RNA (siRNA) and anti-HNP antibody blocking agents and the like, and blocking, neutralizing and reducing the yield, the function and the biological activity of HNP. The siRNA is prepared in vitro through a design and a chemical synthesis method. A HNP-1 polypeptide is produced through a design to be cross-linked with KLH (Keyhole Limpet Hemocyanin) and then to immunize an experimental rabbit, and a rabbit immune globulin is obtained. The same one HNP-1 polypeptide is used for immunizing a mouse, an anti-HNP antibody variable region is prepared, and then a humanized monoclonal anti-HNP-1 antibody is prepared. Both of the siRNA and the anti-HNP-1 antibody can effectively block, neutralize and reduce the yield, the function and the biological activity of HNP, so that the method can be used for treating septicemia and other related diseases caused by bacterial infections.
Owner:MAANSHAN GUOSHENG BIO TECH

Anti-human neutrophil gelatinase-associated lipocalin antibodies and use thereof

The invention relates to anti-human neutrophil gelatinase-associated lipocalin (NGAL) antibodies and a use thereof, and discloses the monoclonal antibodies for specific detection of NGAL and a detection kit containing the monoclonal antibodies. Compared with traditional diagnostic methods and nucleic acid diagnostic methods, the kit not only has the characteristics of fast diagnostic speed, high accuracy degree and high throughput, but also has the characteristics of low cost, simple operation and the like.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Method for increasing granulocyte number in a patient by administering superactive IL-33 fragments

The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.
Owner:CENT NAT DE LA RECHERCHE SCI

Novel application of hyaluronic acid fragment and stable making method

InactiveCN111249302AInhibition removedPromote apoptosisOrganic active ingredientsAntipyreticApoptosis PromoterApoptosis
The invention discloses application of a hyaluronic acid fragment as a human neutrophil migration inhibitor, a human mononuclear cell migration inhibitor, a human mononuclear cell apoptosis promoter and / or a human neutrophil beta sozin secretion promoter. The hyaluronic acid fragment is hyaluronic acid fragment which is of a use structure made through sufficient or slightly excessive sufficient enzymolysis of a high or medium molecular weight hyaluronic acid raw material by using hyaluronidase PH20 with two binding zones, and the hyaluronic acid fragment has an average molecular weight of 35+ / -8KDa. The invention further discloses application of the hyaluronic acid fragment in preparing a medicine for treating neutrophil and mononuclear cell mediated inflammation diseases. The invention further discloses a stable making method of the hyaluronic acid fragment and a combined application method of a hyaluronidase injection and a hyaluronic acid injection made on the basis of the stable making method. Through research, the invention finds the stable making method, making principles and anti-inflammation mechanisms of the hyaluronic acid fragment, and bases are made for medicinal research on the hyaluronic acid fragment.
Owner:QINGDAO AGRI UNIV +2

Enolase peptide conjugate vaccines against staphylococcus aureus

The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologues encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus. The present invention also encompasses methods of treating and / or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.
Owner:MERCK SHARP & DOHME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products